enzastaurin has been researched along with Skin Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, A; Köberle, M; Koczan, D; Kottek, T; Kunz, M; Magin, TM; Saalbach, A; Schönherr, M; Siebolts, U; Simon, JC; Szymczak, S; Wickenhauser, C | 1 |
| Krett, NL; Rosen, ST; Rovedo, MA | 1 |
| Bian, Y; Boye, M; Day, JM; Duvic, M; Hamid, O; Kim, YH; Kuzel, TM; Lin, B; Mark, LA; Musiek, A; Pinter-Brown, L; Porcu, P; Querfeld, C; Rook, AH; Rosen, ST | 1 |
| Guitart, J; Krett, NL; Kuzel, TM; Querfeld, C; Rademaker, A; Rizvi, MA; Rosen, ST; Sabharwal, SS | 1 |
1 trial(s) available for enzastaurin and Skin Neoplasms
| Article | Year |
|---|---|
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hyperkalemia; Indoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Recurrence; Sezary Syndrome; Skin Neoplasms; Treatment Outcome | 2011 |
3 other study(ies) available for enzastaurin and Skin Neoplasms
| Article | Year |
|---|---|
Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.
Topics: Animals; Cell Division; Cell Line, Tumor; Cell Movement; Enzyme Induction; Gene Expression Regulation, Neoplastic; Genomic Library; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Proteins; Nevus, Pigmented; Oligonucleotide Array Sequence Analysis; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Kinases; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Small Interfering; Skin Neoplasms; Transduction, Genetic; Tumor Stem Cell Assay; Up-Regulation | 2014 |
Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.
Topics: Antineoplastic Agents; beta Catenin; Cells, Cultured; Glycogen Synthase Kinase 3; Humans; Hyaluronan Receptors; Indoles; Lymphoma, T-Cell, Cutaneous; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; TCF Transcription Factors; Thiazoles; Urea | 2011 |
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Lymphoma, T-Cell, Cutaneous; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6; Signal Transduction; Skin Neoplasms | 2006 |